ClassID:

21571

A61K51/08 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Sub-classes:
Recent Application in this class:
#1
20260115337
2026-04-30

[177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOF

#2
20260108640
2026-04-23

Peptide Composition for Cancer Approach and Diagnosis

#3
20260042715
2026-02-12

FLUORINATION PROCESS

#4
20260028377
2026-01-29

ANTI-CANCER STRAIN EXPRESSING STREP-TAG, ANTI-CANCER COMPOSITION USING THE SAME, ANTI-CANCER ADJUVANT AND TUMOR IMAGING AGENT

#5
20250375545
2025-12-11

COMPOSITIONS OF AND METHODS OF MAKING FERRITIN-BASED IMAGING AGENTS

#6
20250375499
2025-12-11

IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS

#7
20250346589
2025-11-13

RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS

#8
20250332297
2025-10-30

DLL3-SPECIFIC BINDING CONSTRUCTS AND THEIR USE IN RADIOTHERAPY

#9
20250320259
2025-10-16

METAL-BINDING POLYPEPTIDE

#10
20250264471
2025-08-21

AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING

#11
20250255975
2025-08-14

BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP

#12
20250213697
2025-07-03

INJECTABLE AND/OR SPRAYABLE, IN SITU POLYMERIZABLE COLLAGEN COMPOSITIONS FOR SUSTAINED DELIVERY OF THERAPEUTICS

#13
20250213665
2025-07-03

METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS

#14
20250186632
2025-06-12

FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES

#15
20250186631
2025-06-12

FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES

#16
20250186630
2025-06-12

FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES

#17
20250144249
2025-05-08

METHODS USING SURFACE-EXPRESSIBLE ACTIVATABLE EPITOPES TO LOCALIZE AND/OR TREAT DISEASED CELLS

#18
20250114489
2025-04-10

MASKED IL12 PROTEIN

#19
20250114488
2025-04-10

PSMA-TARGETED RADIOPHARMACEUTICALS AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#20
20250032652
2025-01-30

STABILIZED RADIOPHARMACEUTICAL COMPOSITION

#21
20250022022
2025-01-16

ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION

#22
20240408200
2024-12-12

METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

#23
20240400641
2024-12-05

Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer

#24
20240366812
2024-11-07

Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer

#25
20240342319
2024-10-17

DIAGNOSTIC AND THERAPEUTIC RADIOPHARMACEUTICALS FROM TRIMERIC AMINO ACID MATRIX

#26
20240299598
2024-09-12

METHODS FOR DETECTING CCR2 RECEPTORS

#27
20240285785
2024-08-29

TARGETING SORTILIN

#28
20240270794
2024-08-15

F-18-LABELED COMPOUND FOR POSITRON EMISSION TOMOGRAPHY OF DEAD CELLS AND PREPARATION METHOD THEREFOR

#29
20240247043
2024-07-25

LAG-3 PROTEIN MUTANT, AND PREPARATION AND USE THEREOF

#30
20240226239
2024-07-11

LIGANDS OF THE FSH HORMONE RECEPTOR IN THE DIAGNOSIS AND TREATMENT OF TUMORS

#31
20240218032
2024-07-04

NOVEL HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) SPECIFIC BINDING MOLECULES

#32
20240207457
2024-06-27

CANCER-SPECIFIC POLYPEPTIDE AND USE THEREOF

#33
20240190897
2024-06-13

NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS

#34
20240174729
2024-05-30

HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE

#35
20240174715
2024-05-30

PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS

#36
20240124533
2024-04-18

NEW HER2-BINDING POLYPEPTIDE

#37
20240123097
2024-04-18

Dual-Mode Pharmaceutical Composition for Peptide-Specific Targeted Positron Emission Tomography and Boron Neutron Capture Therapy and the Use Thereof

#38
20240082410
2024-03-14

Bicyclic peptide ligands specific for MT1-MMP

#39
20240066157
2024-02-29

Molecular imaging complex for positron emission tomography

#40
20240050580
2024-02-15

COMPOSITIONS TARGETING TUMOR ASSOCIATED MACROPHAGES AND METHODS USING SAME

#41
20240025945
2024-01-25

PROTEASE-ACTIVATED CONTRAST AGENTS FOR IN VIVO IMAGING

#42
20240016944
2024-01-18

MACROPINOCYTOSIS SELECTIVE MONOBODY-DRUG CONJUGATES

#43
20240002797
2024-01-04

METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

#44
20230383250
2023-11-30

METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

#45
20230382971
2023-11-30

Nanoparticles having molecules that bind or block PD-L1 and uses in treating cancer

#46
20230381324
2023-11-30

SMALL MOLECULE DRUG CONJUGATES

#47
20230365636
2023-11-16

BIOORTHOGONAL REPORTER GENE SYSTEM

#48
20230364183
2023-11-16

CARTILAGE-HOMING PEPTIDES

#49
20230338588
2023-10-26

Granzyme B directed imaging and therapy

#50
20230330239
2023-10-19

EPCAM BINDING FIBRONECTIN TYPE III DOMAINS

#51
20230310662
2023-10-05

METHODS FOR DIAGNOSING AND MONITORING EOSINOPHILIC ESOPHAGITIS

#52
20230285606
2023-09-14

METHODS AND AGENTS FOR THE DETECTION AND TREATMENT OF CANCER

#53
20230265123
2023-08-24

PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT

#54
20230212549
2023-07-06

COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF

#55
20230211000
2023-07-06

Tissue-homing peptide conjugates and methods of use thereof

#56
20220402980
2022-12-22

CHROMOGRANIN A-DERIVED PEPTIDES AND USES THEREOF

#57
20220380409
2022-12-01

CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS

#58
20220296922
2022-09-22

SYSTEMS AND METHODS FOR CREATING CUSTOM BRACHYTHERAPY CARRIERS

#59
20220296738
2022-09-22

CUSTOM BRACHYTHERAPY CARRIERS

#60
20220257805
2022-08-18

PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC, OR IMAGING AGENT TO CD206

#61
20220233704
2022-07-28

MUTANTS AND DRUG CONJUGATES OF R-SPONDINS AND USE THEREOF

#62
20220202966
2022-06-30

POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING

#63
20220169676
2022-06-02

INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES

#64
20220160906
2022-05-26

Compositions of and methods of making ferritin-based imaging agents

#65
20220160905
2022-05-26

FLUORINATION METHOD

#66
20220152230
2022-05-19

DEVICES AND METHODS FOR RADIOPHARMACEUTICAL SYNTHESIS

#67
20220111081
2022-04-14

COMPOSITION FOR TARGETING MEDULLARY THYROID CANCER

#68
20220054662
2022-02-24

Method of detecting eosinophil degranulation in the respiratory tract

#69
20220047729
2022-02-17

MUTANT VARIANTS OF PD-1 RECEPTOR WITH SELECTIVE BINDING TO PD-L1 AND USES THEREOF

#70
20220040499
2022-02-10

BIODEGRADABLE ADHESIVE WITH RADIOISOTOPES

#71
20220023432
2022-01-27

Bicyclic peptide ligands specific for MT1-MMP

#72
20220016276
2022-01-20

COMPOSITION COMPRISING CATALASE, PREPARATION METHOD AND USE THEREOF AND METHOD FOR KILLING TUMOR CELLS

#73
20220016275
2022-01-20

Chelating AAZTA conjugates and complexes thereof

#74
20220016202
2022-01-20

Cartilage-homing peptides

#75
20220008569
2022-01-13

PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS

#76
20220008568
2022-01-13

Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer

#77
20220008565
2022-01-13

Enhanced in Vivo Targeting of Site-Specific Drugs

#78
20220001040
2022-01-06

PD-L1 binding polypeptides for imaging

#79
20220001039
2022-01-06

COMPOSITIONS AND METHODS FOR DETECTING ACE2 EXPRESSION PROFILES

#80
20210395315
2021-12-23

Recombinant lectin and uses thereof

#81
20210395310
2021-12-23

Cyclic Peptide

#82
20210379212
2021-12-09

Stable, concentrated radionuclide complex solutions

#83
20210363161
2021-11-25

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

#84
20210347890
2021-11-11

CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION

#85
20210346529
2021-11-11

Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer

#86
20210346528
2021-11-11

Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer

#87
20210330819
2021-10-28

DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERY CONJUGATES

#88
20210308287
2021-10-07

Method for extraction and purification of 68GA

#89
20210308269
2021-10-07

Small Molecule Drug Conjugates

#90
20210275640
2021-09-09

METHODS FOR ENHANCING PERMEABILITY TO BLOOD-BRAIN BARRIER, AND USES THEREOF

#91
20210268132
2021-09-02

METHODS OF SEQUESTERING TARGET ELEMENTS

#92
20210260205
2021-08-26

CARTILAGE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF

#93
20210253636
2021-08-19

Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics

#94
20210196785
2021-07-01

Methods of diagnosing and treating cervical cancer or a high-grade cervical lesion based on expression of ankyrin-3

#95
20210147510
2021-05-20

Prostate specific membrane antigen binding fibronectin type iii domains

#96
20210138274
2021-05-13

ACCUMULATIVE BORON 10 MEDICINE FOR BORON NEUTRON CAPTURE THERAPY FOR SELECTIVELY OR LOCALLY TARGETING TUMOR TISSUES IN SHORT TIME

#97
20210101936
2021-04-08

Cyclic peptides as protein targeting agents

#98
20210096139
2021-04-01

TAU KINETIC MEASUREMENTS

#99
20210093692
2021-04-01

Methods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase

#100
20210040176
2021-02-11

High affinity PD-1 agents and methods of use

#101
20210015892
2021-01-21

Methods of diagnosing and treating cervical cancer

#102
20200405889
2020-12-31

Methods for detecting CCR2 receptors

#103
20200390912
2020-12-17

Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging

#104
20200384137
2020-12-10

18F labeling of proteins using sortases

#105
20200384136
2020-12-10

Composition comprising catalase, preparation method and use thereof and method for killing tumor cells

#106
20200376146
2020-12-03

NANOBIOLOGIC COMPOSITIONS FOR INHIBITING TRAINED IMMUNITY

#107
20200342600
2020-10-29

SYSTEMS AND METHODS FOR RAPID NEURAL NETWORK-BASED IMAGE SEGMENTATION AND RADIOPHARMACEUTICAL UPTAKE DETERMINATION

#108
20200325231
2020-10-15

Peptides for molecular detection of PD-L1

#109
20200299327
2020-09-24

PROTEASE-ACTIVATED CONTRAST AGENTS FOR IN VIVO IMAGING

#110
20200292534
2020-09-17

Activation of bioluminescene by structural complementation

#111
20200289657
2020-09-17

Bicyclic peptide ligands specific for MT1-MMP

#112
20200268914
2020-08-27

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

#113
20200188539
2020-06-18

Dual targeting ligand for cancer diagnosis and treatment

#114
20200171161
2020-06-04

Bicyclic peptide ligands specific for MT1-MMP

#115
20200140487
2020-05-07

Peptide libraries with non-canonical amino acids

#116
20200123216
2020-04-23

COMPOUNDS WITH REDUCED RING SIZE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME

#117
20200121813
2020-04-23

Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors

#118
20200115391
2020-04-16

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

#119
20200069812
2020-03-05

Cartilage-homing peptide conjugates and methods of use thereof

#120
20200030467
2020-01-30

Stable, concentrated radionuclide complex solutions

#121
20200030465
2020-01-30

Stable, concentrated radionuclide complex solutions

#122
20200017563
2020-01-16

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

#123
20200016282
2020-01-16

Methods for diagnosing and monitoring eosinophilic esophagitis

#124
20200009276
2020-01-09

Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer

#125
20200000944
2020-01-02

MOLECULAR IMAGING CONTRAST AGENTS AND USES THEREOF

#126
20190382435
2019-12-19

Clearing agent

#127
20190361030
2019-11-28

Kit for radiolabelling

#128
20190343972
2019-11-14

PD-L1 binding polypeptides for imaging

#129
20190336580
2019-11-07

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

#130
20190321497
2019-10-24

PET tracer for imaging of neuroendocrine tumors

#131
20190292243
2019-09-26

PEPTIDES AND METHODS OF USE THEREOF

#132
20190282712
2019-09-19

Inhibitor-functionalized ultrasmall nanoparticles and methods thereof

#133
20190256573
2019-08-22

Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer

#134
20190255186
2019-08-22

SINGLE VARIABLE DOMAIN T-CELL RECEPTORS

#135
20190233479
2019-08-01

RECOMBINANT LECTIN AND USES THEREOF

#136
20190225625
2019-07-25

Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

#137
20190224348
2019-07-25

Granzyme B directed imaging and therapy

#138
20190223814
2019-07-25

18F labeled amino acids, derivatives thereof and method of making same

#139
20190192700
2019-06-27

ANTICANCER THERAPY

#140
20190185532
2019-06-20

INHIBITORS

#141
20190177367
2019-06-13

AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING

#142
20190117728
2019-04-25

Cartilage-homing peptides

#143
20190106474
2019-04-11

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#144
20190092858
2019-03-28

CD31 as a molecular target for imaging of inflammation

#145
20190091353
2019-03-28

Radiolabeled drug

#146
20190083664
2019-03-21

PET tracer for imaging of neuroendocrine tumors

#147
20190055279
2019-02-21

NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME

#148
20190054142
2019-02-21

ALPHA-1-MICROGLOBULIN FOR USE IN THE PROTECTION OF KIDNEYS IN CONNECTION WITH USE OF CONTRAST MEDIA

#149
20190046607
2019-02-14

Cyclotides as immunosuppressive agents

#150
20180362616
2018-12-20

VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN

#151
20180353627
2018-12-13

RADIOLABELED DISINTEGRINS AS BRACHYTHERAPY AGENTS

#152
20180333506
2018-11-22

Systems and methods for minimally-invasive assessment of toxicity-induced tissue injury

#153
20180313825
2018-11-01

Activation of bioluminescence by structural complementation

#154
20180306782
2018-10-25

Activation of bioluminescence by structural complementation

#155
20180303755
2018-10-25

Liposomal formulation for the oral hepatic delivery of drugs

#156
20180280549
2018-10-04

RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER

#157
20180280525
2018-10-04

Bicyclic peptide ligands specific for MT1-MMP

#158
20180280523
2018-10-04

Small Molecule Drug Conjugates

#159
20180267050
2018-09-20

Kit for radiolabelling

#160
20180251524
2018-09-06

EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof

#161
20180243369
2018-08-30

Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy

#162
20180221500
2018-08-09

Environmentally sensitive compositions comprising a pH-triggered membrane protein and methods of use thereof in the treatment and diagnosis of tumors

#163
20180215791
2018-08-02

Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells

#164
20180196038
2018-07-12

Activation of bioluminescence by structural complementation

#165
20180193495
2018-07-12

POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING

#166
20180177901
2018-06-28

EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING

#167
20180158559
2018-06-07

METHOD AND SYSTEM FOR PRODUCING GALLIUM-68 RADIOISOTOPE BY SOLID TARGETING IN A CYCLOTRON

#168
20180155395
2018-06-07

Peptidomimetics for imaging the ghrelin receptor

#169
20180147252
2018-05-31

Inhibitors of mitochondrial fission and methods of use thereof

#170
20180095074
2018-04-05

Activation of bioluminescence by structural complementation

#171
20180085479
2018-03-29

Cathepsin-binding compounds bound to a carrier and their diagnostic use

#172
20180066015
2018-03-08

Inhibitors of growth factor activation enzymes

#173
20180037608
2018-02-08

Modified cyclopentapeptides and uses thereof

#174
20180036440
2018-02-08

Methods for diagnosing and monitoring eosinophilic esophagitis

#175
20180021408
2018-01-25

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

#176
20180021373
2018-01-25

Ruthenium and Indium Binding to Gastrins

#177
20180015173
2018-01-18

Conjugates for protection from nephrotoxic active substances

#178
20180005719
2018-01-04

Process for the purification of Ga-68 from eluate deriving from Ge/Ga generators and chromatographic columns for use in said process

#179
20180002375
2018-01-04

Protease-activated contrast agents for in vivo imaging

#180
20170360967
2017-12-21

Collagen targeted imaging probes

#181
20170360956
2017-12-21

Functionalized linear ligands and complexes thereof

#182
20170348442
2017-12-07

COMPOSITIONS AND METHODS FOR DETECTING CCR2 RECEPTORS

#183
20170328906
2017-11-16

Peptides for targeting colorectal cancer, and medical use thereof

#184
20170327536
2017-11-16

NEUROTOXIC TARGET FOR AMYLOSPHEROID, METHOD AND MATERIAL FOR REDUCING THE NEUROTOXICITY OF AMYLOSPHEROID, AND USE THEREOF

#185
20170319722
2017-11-09

CD8-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING

#186
20170312332
2017-11-02

Inhibitors of mitochondrial fission and methods of use thereof

#187
20170307639
2017-10-26

Tau kinetic measurements

#188
20170304471
2017-10-26

Anticancer therapy

#189
20170304284
2017-10-26

Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging

#190
20170283493
2017-10-05

METHODS FOR ENHANCING PERMEABILITY TO BLOOD-BRAIN BARRIER, AND USES THEREOF

#191
20170266260
2017-09-21

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

#192
20170258948
2017-09-14

PD-L1 binding polypeptides for imaging

#193
20170258931
2017-09-14

Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition comprising same

#194
20170239378
2017-08-24

Fluorescent silica-based nanoparticles

#195
20170239327
2017-08-24

Cyclotides as immunosuppressive agents

#196
20170233451
2017-08-17

High affinity PD-1 agents and methods of use

#197
20170231260
2017-08-17

Hydrophobin mimics: process for preparation thereof

#198
20170224831
2017-08-10

Small molecule drug conjugates

#199
20170216465
2017-08-03

Development of neurokinin-1 receptor-binding agent delivery conjugates

#200
20170204150
2017-07-20

Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen

#201
20170121368
2017-05-04

NOVEL COMPOUNDS COMPRISING A BOMBESIN DERIVATIVE, A PROCESS FOR THE PREPARATION THEREOF AND A NUCLEAR MOLECULAR IMAGING AGENT COMPRISING THE SAME

#202
20170115311
2017-04-27

Bacteriophage gene 3 protein compositions and use as amyloid binding agents

#203
20170087252
2017-03-30

Drug conjugates for delivering compounds to senescent cells

#204
20170066807
2017-03-09

LIPOCALIN MUTEINS WITH BINDING-AFFINITY FOR GLYPICAN-3 (GPC-3) AND USE OF LIPOCALIN MUTEINS FOR TARGET-SPECIFIC DELIVERY TO CELLS EXPRESSING GPC-3

#205
20170014351
2017-01-19

Engineered fluorinated biomaterials

#206
20170007727
2017-01-12

METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES

#207
20160355548
2016-12-08

Tumor-targeting polypeptide and application thereof

#208
20160354318
2016-12-08

LIPIDATED GLYCOPROTEIN PARTICLES AND METHODS OF USE

#209
20160347857
2016-12-01

ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)

#210
20160346411
2016-12-01

Activatable fibrin-binding probes

#211
20160326232
2016-11-10

Prostate specific membrane antigen binding fibronectin type III domains

#212
20160303258
2016-10-20

COMPOUNDS AND COMPOSITIONS FOR IMAGING GCC-EXPRESSING CELLS

#213
20160296647
2016-10-13

METHODS TO DIAGNOSE DEGENERATIVE DISC DISEASE

#214
20160282340
2016-09-29

Activation of bioluminescence by structural complementation

#215
20160263260
2016-09-15

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

#216
20160263250
2016-09-15

Imaging beta cell mass

#217
20160256560
2016-09-08

Environmentally sensitive compositions and methods of use thereof

#218
20160251397
2016-09-01

Akt-specific capture agents, compositions, and methods of using and making

#219
20160237118
2016-08-18

Leukemia stem cell targeting ligands and methods of use

#220
20160213793
2016-07-28

Somatostatin analogs with inhibitory activity to growth hormone release

#221
20160208216
2016-07-21

METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

#222
20160206736
2016-07-21

Ligands to radiation-induced molecules

#223
20160199505
2016-07-14

Peptides and peptide/active compound conjugates for renal targeting

#224
20160166717
2016-06-16

Radiolabelling method

#225
20160122406
2016-05-05

ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE

#226
20160121004
2016-05-05

GRP-R agonistic 177-lutetium-labeled bombesin derivatives for diagnosis and treatment of prostate cancer

#227
20160120933
2016-05-05

Inhibitors of mitochondrial fission and methods of use thereof

#228
20160114054
2016-04-28

Conjugates for protection from nephrotoxic active substances

#229
20160069885
2016-03-10

Detection of early-stage pancreatic adenocarcinoma

#230
20160052990
2016-02-25

High affinity PD-1 agents and methods of use

#231
20160039903
2016-02-11

High affinity PD-1 agents and methods of use

#232
20160039882
2016-02-11

Cyclotides as immunosuppressive agents

#233
20160038605
2016-02-11

Porphyrin modified telodendrimers

#234
20160002297
2016-01-07

THERAPEUTIC AGENTS

#235
20150374861
2015-12-31

KIT FOR TUMOR IMAGING

#236
20150374860
2015-12-31

Treatment of metastatic tumors

#237
20150374853
2015-12-31

BRAIN TUMOR TARGETING PEPTIDES AND METHODS

#238
20150352233
2015-12-10

Polypeptide and imaging method

#239
20150335768
2015-11-26

ErbB-2 RECEPTOR TARGETING PEPTIDE

#240
20150315289
2015-11-05

Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)

#241
20150265732
2015-09-24

Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer

#242
20150250903
2015-09-10

Molecular imaging contrast agents and uses thereof

#243
20150246145
2015-09-03

Labelled adrenomedullin derivatives and their use for imaging and therapy.

#244
20150239952
2015-08-27

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#245
20150231284
2015-08-20

MOLECULAR PROBE FOR IMAGING OF PANCREATIC ISLET AND THE PRECURSOR, AND USE OF THE SAME

#246
20150218218
2015-08-06

Peptides that specifically bind HGF receptor (cMet) and uses thereof

#247
20150209453
2015-07-30

PSMA-targeting imaging agents

#248
20150196673
2015-07-16

Anticancer therapy

#249
20150196656
2015-07-16

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

#250
20150165076
2015-06-18

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#251
20150165075
2015-06-18

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy

#252
20150157747
2015-06-11

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

#253
20150151001
2015-06-04

COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE

#254
20150132221
2015-05-14

Methods for diagnosing and monitoring eosinophilic esophagitis

#255
20150112043
2015-04-23

Small peptide specific for lung cancer and application thereof

#256
20150110713
2015-04-23

METHOD AND COMPOSITION FOR TREATING CANCER

#257
20150104381
2015-04-16

Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors

#258
20150087788
2015-03-26

Controlled synthesis of polyglutamates with low polydispersity and versatile architectures

#259
20150078999
2015-03-19

Cyclic peptides as protein targeting agents

#260
20150050213
2015-02-19

COMPOSITIONS AND METHODS FOR IMAGING INFLAMMATION OF TRAUMATIC BRAIN INJURY

#261
20150024458
2015-01-22

Dock-and-lock (DNL) complexes for therapeutic and diagnostic use

#262
20150023873
2015-01-22

EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING

#263
20150010473
2015-01-08

DIAGNOSIS AND TREATMENT OF TUMORS

#264
20150005474
2015-01-01

Recognition molecules for the treatment and detection of tumors

#265
20150004098
2015-01-01

Methods and compositions for treating disorders

#266
20140377178
2014-12-25

Radiofluorination method

#267
20140377177
2014-12-25

Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules

#268
20140377173
2014-12-25

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#269
20140369930
2014-12-18

CYCLOTIDES AS IMMUNOSUPPRESSIVE AGENTS

#270
20140369929
2014-12-18

Ligands to radiation-induced molecules

#271
20140363375
2014-12-11

Activation of bioluminescence by structural complementation

#272
20140357578
2014-12-04

Therapeutic approach for polyglutamine degeneration

#273
20140348747
2014-11-27

Activation of bioluminescence by structural complementation

#274
20140341807
2014-11-20

Pet tracer for imaging of neuroendocrine tumors

#275
20140335022
2014-11-13

Anti-met therapy for previously diagnosed cancer patients

#276
20140335018
2014-11-13

Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

#277
20140274904
2014-09-18

Inhibitors of mitochondrial fission and methods of use thereof

#278
20140271468
2014-09-18

ASTHMA IMAGING

#279
20140227181
2014-08-14

Method of labelling a biologically active molecule with 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose

#280
20140227179
2014-08-14

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#281
20140227175
2014-08-14

Cathepsin-binding compounds bound to a carrier and their diagnostic use

#282
20140179598
2014-06-26

Somatostatin analogs with inhibitory activity to growth hormone release

#283
20140161724
2014-06-12

Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides

#284
20140161723
2014-06-12

In vivo methods of monitoring biodistribution

#285
20140161719
2014-06-12

Porphyrin modified telodendrimers

#286
20140127139
2014-05-08

Compounds for diagnosing diseases associated with the expression of MUC5AC

#287
20140127129
2014-05-08

Dimeric binding proteins based on modified ubiquitins

#288
20140113872
2014-04-24

Agonists and antagonists of the urotensinergic system

#289
20140105819
2014-04-17

In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents

#290
20140100172
2014-04-10

Cancer Imaging and Treatment

#291
20140065068
2014-03-06

Vitamin-targeted imaging agents

#292
20140065065
2014-03-06

Tc imaging agents and methods of use

#293
20140056812
2014-02-27

Imaging beta cell mass

#294
20140051840
2014-02-20

ARSENIC COMPLEXES FOR POTENTIAL DIAGNOSTIC APPLICATIONS

#295
20140044640
2014-02-13

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy

#296
20140039153
2014-02-06

CANCER IMAGING AND TREATMENT

#297
20140004041
2014-01-02

Technetium labelled peptides

#298
20140004039
2014-01-02

RGD mimetic γ-AApeptides and methods of use

#299
20130343990
2013-12-26

Radiolabelled octreotate analogues as PET tracers

#300
20130323172
2013-12-05

Molecular probes for multimodality imaging of anionic membrane surfaces